Literature DB >> 23499907

A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation.

Jinghui Jia1, Yuan Zhang, Jing Cai, Junjie Wang, Hui Ding, Jun Zhou, Fang Fang, Zehua Wang.   

Abstract

Human DNA mismatch repair (MMR) proteins correct DNA errors, which normally occur during DNA replication. Defects of MMR genes result in genomic instability and carcinogenesis. However, the mechanism of MMR proteins regulation has not yet been clearly explored, especially for the member of MutL-related protein, human post meiotic segregation increased 2 (hPMS2). In this study, an inverse correlation between hPMS2 level and activated Akt was detected in nine tumor cell lines by western blot. The negative regulation of hPMS2 expression by activated Akt was further verified by functional experiments manipulating Akt activity using siRNA targeting Akt, Akt Inhibitor I, Akt/PKB Signaling Inhibitor-2 (API-2) and Insulin-like Growth Factor-I (IGF-1). In addition, protein complex immunoprecipitation assays and protein stability assays using cycloheximide revealed that activated Akt (P-Akt1 S473) could bind to hPMS2 directly and induce hPMS2 degradation. Moreover, results of immunofluorescence assays showed blocking Akt activity resulted in accumulation of hPMS2 protein in nucleus. These observations indicate that activated Akt is the upstream signaling regulating hPMS2 expression, stability and nuclear localization, providing a novel insight into the regulation of hPMS2 in cancer cells.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499907     DOI: 10.1016/j.cellsig.2013.02.021

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.

Authors:  Jinghui Jia; Zehua Wang; Jing Cai; Yuan Zhang
Journal:  Tumour Biol       Date:  2015-09-30

2.  Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.

Authors:  Chenchen Feng; Guanxiong Ding; Haowen Jiang; Qiang Ding; Hui Wen
Journal:  Tumour Biol       Date:  2014-12-21

Review 3.  Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Authors:  Qun Liu; Kristen M Turner; W K Alfred Yung; Kexin Chen; Wei Zhang
Journal:  Neuro Oncol       Date:  2014-05-07       Impact factor: 12.300

4.  Akt promotes tumorigenesis in part through modulating genomic instability via phosphorylating XLF.

Authors:  Wenjian Gan; Pengda Liu; Wenyi Wei
Journal:  Nucleus       Date:  2015-07-30       Impact factor: 4.197

5.  Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells.

Authors:  Xin Guo; Nan Guo; Jianwen Zhao; Yunlang Cai
Journal:  Oncol Rep       Date:  2017-07-18       Impact factor: 3.906

Review 6.  Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy.

Authors:  Changxian Shen; Yuqi He; Qiang Chen; Haihua Feng; Terence M Williams; Yuanzhi Lu; Zhengfu He
Journal:  Ann Transl Med       Date:  2021-10

7.  Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.

Authors:  Sofia Sagredou; Panagiotis Dalezis; Eirini Papadopoulou; Maria Voura; Maria V Deligiorgi; Michail Nikolaou; Mihalis I Panayiotidis; George Nasioulas; Vasiliki Sarli; Dimitrios T Trafalis
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

8.  Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.

Authors:  Si Sun; Simei Zhao; Qiang Yang; Wenwen Wang; E Cai; Yiping Wen; Lili Yu; Zehua Wang; Jing Cai
Journal:  Cancer Sci       Date:  2018-05-15       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.